Sugi Predict

Sugi Predict / Compounds / Bremelanotide

Bremelanotide

Bremelanotide

SCHEMBL14498253

CCCCC(NC(C)=O)C(=O)NC1CC(=O)NCCCCC(C(=O)O)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CCCNC(=N)N)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC1=O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MC4R

The experimentally established mechanism targets of Bremelanotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ MC4R known ✓ P32245 20/20 0.71
▸ MC3R P41968 8/20 0.71
▸ MC1R Q01726 5/20 0.71
▸ MC5R P33032 5/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bremelanotide SCHEMBL13574795 1.00 MC4R (0.71) MC4RMC3RMC1RMC5R
Bremelanotide SCHEMBL20356841 1.00 MC4R (0.71) MC4RMC3RMC1RMC5R
Bremelanotide SCHEMBL20356840 1.00 MC4R (0.71) MC4RMC3RMC1RMC5R
Bremelanotide SCHEMBL29405727 1.00 MC4R (0.71) MC4RMC3RMC1RMC5R
Bremelanotide SCHEMBL29575881 0.99 MC4R (0.70) MC4RMC3RMC1RMC5R
SCHEMBL13064154 0.98 MC4R (0.67) MC4RMC3RMC1RMC5R
Melatonan SCHEMBL29473785 0.97 MC4R (0.67) MC4RMC3RMC1RMC5R
SCHEMBL13064117 0.96 MC4R (0.66) MC4RMC3RMC1RMC5R
SCHEMBL10307917 0.95 MC4R (0.66) MC4RMC3RMC1RMC5R
SCHEMBL19473791 0.95 MC4R (0.66) MC4RMC3RMC1RMC5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235625-B2 Multiple agent therapy for sexual dysfunction PALATIN TECHNOLOGIES, INC. (US) 2007-06-26 — — US disclosed
Send feedback